Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, targeted therapies, and surgery techniques.

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

The Human Epidermal Growth Factor Receptor 2 (HER2) is one of the aggressive subtypes of breast cancer. The HER2 status decides the requirement of breast cancer patients to receive HER2-targeted ...

Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of pelareorep, an investigational oncolytic virus ...